<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019808</url>
  </required_header>
  <id_info>
    <org_study_id>LEGACY-3</org_study_id>
    <nct_id>NCT04019808</nct_id>
  </id_info>
  <brief_title>Gastric Cancer Risk Factors Knowledge in European and Latinoamerican Population</brief_title>
  <acronym>LEGACY-3</acronym>
  <official_title>Interventional Study at the Primary and Secondary Levels of Prevention for Knowledge Regarding GC Risk Factors in EU and CELAC Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vall d'Hebron Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INSTITUTO ALEXANDER FLEMING</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Central del IPS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO PCUP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is divided into two parts:

      Part 1: An interventional study, with a pre-post study design to determinate the grade of
      knowledge of established GC risk factors.

      Part 2: An observacitonal study to know impact on prevalence and infection eradication of H.
      pylori
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: to determinate the grade of knowledge of established GC risk factors and
      identification of attitudes about, GC screening programs at baseline, prior to the
      intervention though an educational program.

      Part 2: to generate an H. pylori registry, to know its impact on prevalence and infection
      eradication rate at 6th, 12th, 24th and at Month 36th.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>knowledge GC risk factors and symptoms</measure>
    <time_frame>3 years</time_frame>
    <description>Compare the results obtained through a knowledge of CG risk factors by study-specific questionnaire before and after an educational intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>H. pylori prevalence and drug resistance</measure>
    <time_frame>3 years</time_frame>
    <description>Generate an H. pylori registry, to know its impact on prevalence and infection eradication rate at months 6th, 12th, 24th and 36th.</description>
  </primary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Gastric Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Part 1:

        Subjects &gt;18 years old whom able to answer the questions structured in the survey.

        Part 2:

        Subjects &gt;18 years old diagnose from H. pylori infection
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Part A: Educational Intervention Inclusion criteria

          -  Subjects &gt;18 years old, from EU and CELAC countries participating in this study.

          -  Has given and signed the IC to participate in this study. Exclusion criteria

          -  Subjects who have received some prior preparation (Cancer Gastric Information).

          -  Subjects who have previous Knowledge in Gastric Cancer (Example, near relatives who
             have suffered Gastric Cancer

        Part B: H. pylori Register Inclusion criteria

          -  Subjects ≥18 years old diagnose from H. pylori infection and treated at participant
             sites

          -  Has given and signed the IC. Exclusion criteria

          -  Subjects with chronic gastritis without confirmed diagnose of H. pylori infection,
             pathologically of by urease test.

          -  Patient's with CG diagnosis (including gastroesophageal junction cancer).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Andrés Cervantes, MD</last_name>
    <phone>0034961973543</phone>
    <email>andres.cervantes@uv.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tania Fleitas, MD</last_name>
    <phone>0034961973543</phone>
    <email>tfleitask@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Alexander Fleming</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426NZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Manuel O'Connor, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Católica de Chile</name>
      <address>
        <city>Santiago</city>
        <zip>8331150</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología</name>
      <address>
        <city>Mexico</city>
        <zip>01480</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>VU Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Derks, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GenPat</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Caballero, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Pathology and Immunology of University of Porto</name>
      <address>
        <city>Porto</city>
        <zip>4200 135</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fátima Carneiro, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (VHIO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Alsina, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Investigación Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Cervantes, MD PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>tania Fleitas, MD PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Paraguay</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Personalized medicine</keyword>
  <keyword>Oncology</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Primary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

